Ode to oseltamivir and amantadine?

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 17, Issue 1, 2006, Pages 11-14

  Conly, J M ^a,c   Johnston, B L ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c FOOTHILLS HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; HEMAGGLUTININ; INTERLEUKIN 1; OSELTAMIVIR; RIMANTADINE; SIALIDASE; TUMOR NECROSIS FACTOR; ZANAMIVIR;

AVIAN INFLUENZA; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME ACTIVITY; EPIDEMIC; GEOGRAPHIC DISTRIBUTION; HALLUCINATION; HEALTH CARE ORGANIZATION; HUMAN; INFLUENZA; INFLUENZA A; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INSOMNIA; META ANALYSIS; NAUSEA; NOTE; SYSTEMATIC REVIEW; VIRUS REPLICATION; VIRUS VECTOR;

EID: 33645665930     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/106989     Document Type: Note

References (30)

1. Nicholson KG, Wood JM, Zambon M. Influenza. Lancet 2003;362:1733-45.
2. Liu C, Air GM. Selection and characterization of a neuraminidase-minus mutant of influenza virus and its rescue by cloned neuraminidase genes. Virology 1993;194:403-7.
3. Buck P, Herman S, Scott C, et al. Respiratory virus surveillance. FluWatch project, 1997-1998. Can Commun Dis Rep 1998;24:49-51.
4. Colman PM. Neuraminidase: Enzyme and antigen. In: Krug RM, ed. The Influenza Viruses. New York: Plenum Press, 1989:175-218.
5. Colman PM. Influenza virus neuraminidase: Structure, antibodies, and inhibitors. Protein Sci 1994;3:1687-96.
6. Schultz-Cherry S, Hinshaw VS. Influenza virus neuraminidase activates latent transforming growth factor beta. J Virol 1996;70:8624-29.
7. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005;54(RR-8):1-40. (Erratum in 2005;54:750).
8. Beigel JH, Farrar J, Han AM, et al; Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005;353:1374-85.
9. Horimoto T, Kawaoka Y. Pandemic threat posed by avian influenza A viruses. Clin Microbiol Rev 2001;14:129-49.
10. Centers for Disease Control and Prevention (CDC). Update: Isolation of avian influenza A(H5N1) viruses from humans - Hong Kong, 1997-1998. MMWR Morb Mortal Wkly Rep 1998;46:1245-7.
11. Claas EC, Osterhaus AD, van Beek R, et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998;351:472-7. (Erratum in 1998;351:1292).
12. Lee SY, Mak KH, Saw TA. The avian flu (H5N1): One year on. Department of Health, Hong Kong Special Administrative Region of China. Public Health and Epidemiology Bulletin 1999;8:1-7.
13. Mounts AW, Kwong H, Izurieta HS, et al. Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997. J Infect Dis 1999;180:505-8.
14. Buxton Bridges C, Katz JM, Seto WH, et al. Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong. J Infect Dis 2000;181:344-8.
15. Katz JM, Lim W, Bridges CB, et al. Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J Infect Dis 1999;180:1763-70.
16. World Health Organization (WHO). Avian influenza A(H5N1) - update 32: Situation (human) in Thailand. 〈www.who.int/csr/don/2004_03_09/en〉 (Version current at February 1, 2006).
17. Centers for Disease Control and Prevention. Key facts about avian influenza (bird flu) and avian influenza A (H5N1) virus 〈www.cdc.gov/flu/ avian/gen-info/facts.htm〉 (Version current at February 1, 2006).
18. World Health Organization. Cumulative Number of Confirmed Human Cases of Avian Influenza A(H5N1) since 28 January 2004. 〈www.who.int/csr/disease/ avian_influenza/country/cases_table_2005_01_26/en〉 (Version current at February 1, 2006).
19. Aoki F. Amantadine and rimantadine. In: KG Nicholson, RG Webster, AJ Hay, eds. Textbook of influenza. Oxford: Blackwell Science, 1998:457-76.
20. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005;353:1363-73.
21. Centers for Disease Control and Prevention (CDC). High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents - United States, 2005-06 influenza season. MMWR Morb Mortal Wkly Rep 2006;55:44-6.
22. Belshe RB, Smith MH, Hall CB, Betts R, Hay AJ. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J Virol 1988;62:1508-12.
23. Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern. Lancet 2005;366:1175-81.
24. Public Health Agency of Canada. Interim recommendation for use of amantadine for influenza. 〈www.phac-aspc.gc.ca/media/advisories_avis/2006/ statment060115.html〉 (Version current at February 3, 2006).
25. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A. Antivirals for influenza in healthy adults: Systematic review. Lancet 2006;367:303-13.
26. Yuen KY, Wong SS. Human infection by avian influenza A H5N1. Hong Kong Med J 2005;11:189-99.
27. de Jong MD, Tran TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005;353:2667-72.
28. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001;20:127-133. (Erratum in 2001;20:421).
29. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: Descriptive study. Lancet 2004;364:759-65.
30. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005;55(Suppl 1):i5-i21.